[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623556":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":11,"centralContacts":24,"locations":31,"responsibleParty":49,"collaborators":11,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":11,"enrollmentInfo":61,"targetDuration":11,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":34,"whyStopped":11,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental arm","EXPERIMENTAL",null,[13,14],"Other: Blood sampling","Other: Lumbar puncture",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"Blood sampling","At the diagnosis of meningioma recurrence: a blood sample of 28 mL of whole blood (i.e., 4 EDTA tubes of 7 mL each) and at the end of meningioma recurrence treatment: a blood sample of 28 mL of whole blood (i.e., 4 EDTA tubes of 7 mL each) will be collect.",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"Lumbar puncture","At the time of diagnosis of meningioma recurrence :a cerebrospinal fluid (CSF) sample obtained by lumbar puncture, in the absence of contraindications verified by the investigator, collected in one dry tube of 4 mL.",[9],[25],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},"Julien BOETTO, Dr","CONTACT","0467337488","+33","j-boetto@chu-montpellier.fr",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":36,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"CHU de Montpellier","RECRUITING","Montpellier","France","34295","FR",{"type":40,"coordinates":41},"Point",[42,43],3.87635,43.61093,{"lat":43,"lon":42},[46,47],{"name":26,"role":27,"phone":28,"phoneExt":29,"email":30},{"name":26,"role":48,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"type":50,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623556","search-for-circulating-tumour-cells-in-the-blood-andor-cerebrospinal-fluid-in-patients-with-recurrent-aggressive-meningiomas-proof-of-concept-study-100623556",false,"NCT07398170","Search for Circulating Tumour Cells in the Blood and\u002For Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas: Proof-of-concept Study","Search for Circulating Tumour Cells in the Blood and\u002For Cerebrospinal Fluid in Patients With Recurrent Aggressive Meningiomas That Have Recurred: Proof-of-concept Study","BIOLIMEN-1","Inclusion Criteria:\n\n* Over 18 years of age\n* Operated on for a grade 2 or 3 meningioma at Montpellier University Hospital between 2015 and 2024\n* Tumour expressing SSTR2A on the initial surgical specimen\n* Clinical and\u002For radiological recurrence as determined by MRI imaging (progression of a residual lesion OR appearance of a new lesion consistent with a meningioma at the surgical site or elsewhere)\n\nExclusion Criteria:\n\n* Other active ongoing cancer\n* Contraindications to lumbar puncture:\n* Intracranial hypertension with meningioma exerting a mass effect and obstruction of the cerebrospinal fluid (CSF) pathway\u002Frisk of trans-tentorial or amygdalar herniation\n* Blood clotting disorder with risk of haematoma at the puncture site (anticoagulant treatment at therapeutic dose or antiplatelet therapy, thrombocytopenia or thrombopathy)\n* Infection at the puncture site\n* Pregnant or breastfeeding women (Article L.1121-5 of the French Public Health Code)\n* Persons deprived of their liberty by judicial or administrative decision (Article L.1121-6 of the French Public Health Code)\n* Persons who are subject to legal protection measures or who are unable to express their consent (guardianship, curatorship, judicial protection; Article L.1121-8 of the French Public Health Code)\n* Not affiliated with a social security scheme or beneficiary of such a scheme (Article L.1121-8-1 of the French Public Health Code)\n* Persons participating in another study that includes an ongoing exclusion period (Article L.1121-12 of the French Public Health Code)\n* Failure to obtain written informed consent","ALL","18 Years",{"count":62,"type":63},15,"ESTIMATED","INTERVENTIONAL",[66],"NA","The goal of the clinical trial is to assess the presence of circulating tumor cells (CTCs) in the blood and\u002For cerebrospinal fluid (CSF) of patients with aggressive recurrent meningiomas.",[69],"Meningioma",[71,72,73,74,75,76],"Meningioma diagnosis","Circulating tumor cells","Liquid Biopsy","Neoplasm Recurrence, Local","Therapy","Biomarkers","2026-07-13",{"date":79,"type":80},"2026-07-14","ACTUAL",{"date":77,"type":80},{"date":83,"type":63},"2027-10",{"name":5,"class":6},1]